JP2020517611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517611A5 JP2020517611A5 JP2019556610A JP2019556610A JP2020517611A5 JP 2020517611 A5 JP2020517611 A5 JP 2020517611A5 JP 2019556610 A JP2019556610 A JP 2019556610A JP 2019556610 A JP2019556610 A JP 2019556610A JP 2020517611 A5 JP2020517611 A5 JP 2020517611A5
- Authority
- JP
- Japan
- Prior art keywords
- mesylate salt
- salt according
- organic solvent
- represented
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 15
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 239000003960 organic solvent Substances 0.000 claims 7
- 102000001301 EGF receptor Human genes 0.000 claims 6
- 108060006698 EGF receptor Proteins 0.000 claims 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- 239000013078 crystal Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 238000000113 differential scanning calorimetry Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 239000012046 mixed solvent Substances 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- -1 4- (4-((dimethylamino) methyl) -3-phenyl-1H-pyrazole-1-yl) pyrimidin-2-ylamino Chemical group 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 0 CCNC(C*(C)CC*(C)(C)C)**C Chemical compound CCNC(C*(C)CC*(C)(C)C)**C 0.000 description 6
- HAFZSBASGRZPLA-UHFFFAOYSA-N CCC(C)N(C)CC Chemical compound CCC(C)N(C)CC HAFZSBASGRZPLA-UHFFFAOYSA-N 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129468A JP7390444B2 (ja) | 2017-04-21 | 2022-08-16 | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0051687 | 2017-04-21 | ||
| KR20170051687 | 2017-04-21 | ||
| PCT/KR2018/004473 WO2018194356A1 (en) | 2017-04-21 | 2018-04-18 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129468A Division JP7390444B2 (ja) | 2017-04-21 | 2022-08-16 | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517611A JP2020517611A (ja) | 2020-06-18 |
| JP2020517611A5 true JP2020517611A5 (enExample) | 2021-04-30 |
| JP7126514B2 JP7126514B2 (ja) | 2022-08-26 |
Family
ID=63857137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556610A Active JP7126514B2 (ja) | 2017-04-21 | 2018-04-18 | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス |
| JP2022129468A Active JP7390444B2 (ja) | 2017-04-21 | 2022-08-16 | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129468A Active JP7390444B2 (ja) | 2017-04-21 | 2022-08-16 | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11453656B2 (enExample) |
| EP (1) | EP3612529A4 (enExample) |
| JP (2) | JP7126514B2 (enExample) |
| KR (3) | KR102629654B1 (enExample) |
| CN (1) | CN110869367B (enExample) |
| AR (1) | AR111469A1 (enExample) |
| AU (2) | AU2018256227B2 (enExample) |
| CA (1) | CA3059543A1 (enExample) |
| CO (1) | CO2019011578A2 (enExample) |
| EA (1) | EA201992501A1 (enExample) |
| IL (2) | IL294666B2 (enExample) |
| MA (1) | MA49696A (enExample) |
| MX (2) | MX392634B (enExample) |
| MY (1) | MY201919A (enExample) |
| NZ (1) | NZ758443A (enExample) |
| PH (1) | PH12019502370A1 (enExample) |
| SA (1) | SA519410342B1 (enExample) |
| SG (1) | SG11201909615YA (enExample) |
| TW (1) | TWI776882B (enExample) |
| UA (1) | UA124364C2 (enExample) |
| WO (1) | WO2018194356A1 (enExample) |
| ZA (1) | ZA201907687B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| MX393995B (es) | 2017-07-28 | 2025-03-24 | Yuhan Corp | Proceso mejorado para preparar derivados de aminopirimidina |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| KR101973074B1 (ko) * | 2018-11-30 | 2019-04-26 | 주식회사 티움바이오 | 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물 |
| JP7240032B2 (ja) * | 2018-12-21 | 2023-03-15 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | プロテインキナーゼ活性を阻害するためのアミノピリミジン系化合物 |
| MX2021010265A (es) | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| JP2022531980A (ja) * | 2019-05-14 | 2022-07-12 | ヤンセン バイオテツク，インコーポレーテツド | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法 |
| US11850248B2 (en) * | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
| US20240270733A1 (en) * | 2021-06-01 | 2024-08-15 | Hangzhou Solipharma Co., Ltd. | Hydrate form of lazertinib mesylate, preparation method thereof and use thereof |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| WO2025052273A1 (en) | 2023-09-05 | 2025-03-13 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100569753C (zh) | 2003-12-25 | 2009-12-16 | 卫材R&D管理有限公司 | 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酰胺的甲磺酸盐的结晶（c）及其制备方法 |
| WO2005077933A1 (en) | 2004-02-11 | 2005-08-25 | Natco Pharma Limited | Novel polymorphic form of imatinib mesylate and a process for its preparation |
| SG10201510696RA (en) * | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| CZ2009570A3 (cs) | 2009-08-26 | 2011-03-09 | Zentiva, K. S. | Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem |
| JP5740409B2 (ja) | 2009-11-13 | 2015-06-24 | ジェノスコ | キナーゼ阻害剤 |
| EP2649060B1 (en) * | 2010-12-06 | 2017-04-05 | MSN Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
| EP2736895B1 (en) * | 2011-07-27 | 2016-01-06 | Astrazeneca AB | 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| CN104540822B (zh) | 2013-07-08 | 2016-08-31 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的晶型及其制备方法 |
| CN106687457B (zh) | 2014-05-13 | 2020-01-10 | 阿里亚德医药股份有限公司 | 用于激酶抑制的杂芳基化合物 |
| MX2017003181A (es) * | 2014-10-13 | 2017-07-20 | Yuhan Corp | Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico. |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| KR101794186B1 (ko) | 2015-10-30 | 2017-11-08 | 한국기술교육대학교 산학협력단 | 전기자동차용 급전장치 |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
-
2018
- 2018-04-13 AR ARP180100945A patent/AR111469A1/es not_active Application Discontinuation
- 2018-04-18 CN CN201880026342.7A patent/CN110869367B/zh active Active
- 2018-04-18 WO PCT/KR2018/004473 patent/WO2018194356A1/en not_active Ceased
- 2018-04-18 IL IL294666A patent/IL294666B2/en unknown
- 2018-04-18 MA MA049696A patent/MA49696A/fr unknown
- 2018-04-18 EP EP18787260.1A patent/EP3612529A4/en active Pending
- 2018-04-18 UA UAA201911263A patent/UA124364C2/uk unknown
- 2018-04-18 JP JP2019556610A patent/JP7126514B2/ja active Active
- 2018-04-18 CA CA3059543A patent/CA3059543A1/en active Pending
- 2018-04-18 TW TW107113234A patent/TWI776882B/zh active
- 2018-04-18 KR KR1020180044850A patent/KR102629654B1/ko active Active
- 2018-04-18 NZ NZ758443A patent/NZ758443A/en unknown
- 2018-04-18 SG SG11201909615Y patent/SG11201909615YA/en unknown
- 2018-04-18 US US16/605,944 patent/US11453656B2/en active Active
- 2018-04-18 EA EA201992501A patent/EA201992501A1/ru unknown
- 2018-04-18 MX MX2019012574A patent/MX392634B/es unknown
- 2018-04-18 AU AU2018256227A patent/AU2018256227B2/en active Active
- 2018-04-18 MY MYPI2019006145A patent/MY201919A/en unknown
- 2018-04-18 IL IL270018A patent/IL270018B/en unknown
-
2019
- 2019-10-18 CO CONC2019/0011578A patent/CO2019011578A2/es unknown
- 2019-10-18 PH PH12019502370A patent/PH12019502370A1/en unknown
- 2019-10-20 SA SA519410342A patent/SA519410342B1/ar unknown
- 2019-10-21 MX MX2022006357A patent/MX2022006357A/es unknown
- 2019-11-20 ZA ZA2019/07687A patent/ZA201907687B/en unknown
-
2022
- 2022-03-17 US US17/697,655 patent/US11981659B2/en active Active
- 2022-05-23 AU AU2022203486A patent/AU2022203486B2/en active Active
- 2022-08-16 JP JP2022129468A patent/JP7390444B2/ja active Active
-
2023
- 2023-12-18 KR KR1020230184208A patent/KR102835717B1/ko active Active
-
2024
- 2024-03-27 US US18/618,379 patent/US12428401B2/en active Active
-
2025
- 2025-07-11 KR KR1020250093917A patent/KR20250111074A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517611A5 (enExample) | ||
| TWI640509B (zh) | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 | |
| TWI597277B (zh) | 一種酪胺酸激酶抑制劑的二馬來酸鹽的第ｉ型結晶及製備方法 | |
| JP6158811B2 (ja) | ４−［５−（ピリジン−４−イル）−１ｈ−１，２，４−トリアゾール−３−イル］ピリジン−２−カルボニトリルの結晶多形およびその製造方法 | |
| CN115461344B (zh) | 一种glp-1受体激动剂的晶型a及其制备方法 | |
| JP6830888B2 (ja) | Ｊａｋ阻害剤の硫酸水素塩の結晶形およびその製造方法 | |
| CN110869367A (zh) | 氨基吡啶衍生物化合物的盐、其结晶形式、以及用于制备它们的方法 | |
| JP2020033359A5 (enExample) | ||
| JP2019504033A (ja) | 選択的なｓ１ｐ１受容体アゴニストの新規な結晶形及びその製造方法 | |
| WO2017152707A1 (zh) | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 | |
| JP7314319B2 (ja) | Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途 | |
| JP2025128238A (ja) | オキサゾール化合物結晶 | |
| JP2023553021A (ja) | ピロロピリミジン系化合物の塩、その結晶及びその使用 | |
| US20220363655A1 (en) | Salt and solid state forms of escatalopram | |
| JP2025114691A (ja) | オキサゾール化合物結晶 | |
| CN111989329A (zh) | 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法 | |
| CN101277694B (zh) | 盐酸伊立替康的新晶形 | |
| CN104628677A (zh) | 一种沃替西汀有机酸盐晶型及其制备方法 | |
| CN104610195A (zh) | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 | |
| JP2018509421A (ja) | ニンテダニブジエタンスルホン酸塩結晶並びにその製造方法および使用 | |
| JPWO2020151756A5 (enExample) | ||
| CN118525012A (zh) | 奥希替尼共晶及制备方法以及作为药物或在药物制剂中的应用 | |
| JP2018500355A5 (enExample) | ||
| CN106478603B (zh) | 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途 | |
| CN119569705B (zh) | Ptk抑制剂a的磷酸盐及应用 |